Kodiak Sciences Inc.

Phase 3 Confirmed

Zenkuda

diabetic retinopathy

Resolved

103days ago

Phase 3 readout · Mar 26, 2026

What's at stake Phase 3 trial results for Zenkuda in diabetic retinopathy are due Mar 26, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 13h ago

“On March 26, 2026, Kodiak Sciences Inc. (the “Company”) issued a press release announcing positive topline results in GLOW2, the Company’s second Phase 3 study in diabetic retinopathy, demonstrating superiority of Zenkuda ™ (tarcocimab tedr”

Add to calendar Post on X Reddit

Provenance